Frequency of adverse events
| Bevacizumab (N=154) | Ranibizumab (N=163) | p Value | |
|---|---|---|---|
| Total number | 19 | 15 | 0.37 |
| Death | 3 | 2 | 0.61 |
| Vascular disorders | |||
| Heart attack | 3 | 2 | 0.61 |
| Stroke | 1 | 1 | 0.94 |
| Mesenteric artery occlusion | 1 | 0 | 0.3 |
| Non-vascular disorders | |||
| Arrhythmia | 1 | 1 | 0.94 |
| Nervous system | 2 | 1 | 0.53 |
| Infection | 3 | 3 | 0.94 |
| Injury or procedural complication | 2 | 3 | 0.70 |
| Benign or malignant neoplasm | 1 | 2 | 0.60 |
| Surgical or medical procedure | 1 | 0 | 0.30 |
| Gastrointestinal disorder | 0 | 0 | 1.0 |
| Any other system organ class | 3 | 2 | 0.61 |
| Ocular event | 0 | 0 | 1.0 |